Entera Bio (NASDAQ:ENTX – Get Free Report) and HilleVax (NASDAQ:HLVX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.
Volatility & Risk
Entera Bio has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
Earnings & Valuation
This table compares Entera Bio and HilleVax’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entera Bio | $130,000.00 | 580.74 | -$8.89 million | ($0.28) | -7.54 |
| HilleVax | N/A | N/A | -$123.57 million | ($3.30) | -3.88 |
Profitability
This table compares Entera Bio and HilleVax’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entera Bio | N/A | -103.40% | -85.00% |
| HilleVax | N/A | -56.18% | -43.75% |
Analyst Recommendations
This is a summary of recent ratings for Entera Bio and HilleVax, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entera Bio | 0 | 0 | 1 | 0 | 3.00 |
| HilleVax | 0 | 0 | 4 | 0 | 3.00 |
Entera Bio currently has a consensus target price of $10.00, suggesting a potential upside of 373.93%. HilleVax has a consensus target price of $29.00, suggesting a potential upside of 126.56%. Given Entera Bio’s higher probable upside, analysts clearly believe Entera Bio is more favorable than HilleVax.
Institutional and Insider Ownership
14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 8.9% of Entera Bio shares are owned by insiders. Comparatively, 71.1% of HilleVax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
HilleVax beats Entera Bio on 6 of the 11 factors compared between the two stocks.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
About HilleVax
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
